Approved Treatments

Soliris

Soliris (eculizumab) is a terminal complement inhibitor developed by Alexion for the treatment of atypical hemolytic uremic syndrome (aHUS).

Read more on Soliris

Ultomiris

Ultomiris (ravulizumab-cwvz) is a humanized monoclonal antibody that Alexion developed to treat atypical hemolytic uremic syndrome (aHUS).

Read more on Ultomiris